激活CD4T细胞的新抗原增强了个性化癌症疫苗的疗效
Amanda L Huff1,2,3, Gabriella Longway1,2,3, Jacob T Mitchell1,2,3,4
1Johns Hopkins Convergence Institute and.
JCI insight
|December 8, 2023
概括
在个性化癌症疫苗中包括CD4+T细胞点,可以增强抗瘤CD8+T细胞的反应,改善存活率. 这种方法创造了一个不那么免疫抑制的瘤微环境,提高了疫苗的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 疫苗开发 疫苗开发
背景情况:
- 个性化癌症疫苗通常集中在CD8+T细胞激活上.
- CD4+ T 细胞激活在疫苗诱导的临床益处中的作用尚不清楚.
- 以前的个性化新抗原疫苗需要检查点抑制剂才能有效.
研究的目的:
- 研究将CD4+T细胞新抗原纳入个性化癌症疫苗中的影响.
- 评估针对 MHCI 和 MHCII 特定新抗原的疫苗的治疗疗效.
- 评估对瘤微环境和T细胞反应的影响.
主要方法:
- 开发一种双标疫苗 (PancVAX2),包括CD4+T细胞新抗原.
- 瘤携带小鼠的疫苗接种和瘤生长和存活率的评估.
- 分析CD8+T细胞原始化,招募,PD-1表达和CD4+T细胞 (Th1) 反应.
- 对调节性T细胞 (Tregs),髓状细胞衍生的抑制细胞和M1-类巨细胞的评估.
主要成果:
- 在没有检查点抑制剂的情况下,PancVAX2显著改善了瘤生长控制和长期存活率.
- 双标疫苗增强了CD8+ T细胞的反应,并减少了PD-1的表达.
- 新抗原特异性CD4+ T细胞与降低Tregs和较少免疫抑制瘤微环境相关.
- 在接受PancVAX2治疗的瘤中观察到增多的亲炎性髓状细胞和M1巨细胞.
结论:
- 优先考虑和包括CD4+T细胞新抗原对于有效的个性化癌症疫苗至关重要.
- 针对CD4+和CD8+T细胞新抗原,可以增强抗瘤免疫力.
- 这一策略为改善癌症疫苗治疗提供了一个有希望的方法.
相关概念视频
Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
T Cell Activation and Clonal Selection
741
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
741
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


